Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0600139 (
Prostate Cancer
)
4,540
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vitamin D may influence prostate cancer risk, but evidence is inconsistent. We conducted a nested case-control study in the
Prostate Cancer
Prevention Trial (PCPT). Cases (
n
= 1,128) and controls (
n
= 1,205) were frequency matched on age, first-degree relative with prostate cancer, and PCPT treatment arm (finasteride/placebo); African-Americans were oversampled and case/control status was biopsy confirmed. We selected 21 SNPs in vitamin D-related genes
(VDR, GC,
C10orf88
, CYP2R1, CYP24A1, CYP27B1, DHCR7
, and
NADSYN1
) to test genotype and genotype-treatment interactions in relation to prostate cancer. We also tested mean serum 25(OH)D differences by minor allele distributions and tested for serum 25(OH)D-genotype interactions in relation to prostate cancer risk. Log-additive genetic models (Bonferroni-corrected within genes) adjusted for age, body mass index, PSA, and family history of prostate cancer revealed a significant interaction between treatment arm and
GC
/rs222016 (finasteride OR = 1.37, placebo OR = 0.85;
P
interaction
< 0.05),
GC
/rs222014 (finasteride OR = 1.36, placebo OR = 0.85;
P
interaction
< 0.05), and
CYP27B1
/rs703842 (finasteride OR = 0.76, placebo OR = 1.10;
P
interaction
< 0.05) among Caucasians, and
C10orf88
/rs6599638 (finasteride OR = 4.68, placebo OR = 1.39;
P
interaction
< 0.05) among African-Americans.
VDR/
rs1544410 and
CYP27B1
/rs703842 had significant treatment interactions for high-grade disease among Caucasians (finasteride OR = 0.81, placebo OR = 1.40;
P
interaction
< 0.05 and finasteride OR = 0.70, placebo OR = 1.28;
P
interaction
< 0.05, respectively). Vitamin D-related SNPs influenced serum 25(OH)D, but gene-serum 25(OH)D effect modification for prostate cancer was marginally observed only for
CYP24A1
/rs2248359. In conclusion, evidence that vitamin D-related genes or gene-serum 25(OH)D associations influence prostate cancer risk is modest. We found some evidence for gene-finasteride interaction effects for prostate cancer in Caucasians and African-Americans. Results suggest only minimal associations of vitamin D with total or high-grade prostate cancer.
...
PMID:Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. 3210 46